Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab Induction and Maintenance in Poor Risk CLL
NCT01809847Phase 2Completed
- Sponsor
- Technische Universität Dresden
- Start
- Mar 2013
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in chronic lymphocytic leukemia (CLL), sponsored by Technische Universität Dresden. Started Mar 2013; status: completed.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01809847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01809847.